​

Regencell Bioscience (RGC) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

RGC Stock Rating

Regencell Bioscience stock's rating consensus is Hold, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (25.00%), 3 Hold (75.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 4 0 3 1 Strong Sell Sell Hold Buy Strong Buy

RGC Price Target Upside V Benchmarks

TypeNameUpside
StockRegencell Bioscience-
SectorHealthcare Stocks 19.91%
IndustrySpecialty & Generic Drug Manufacturers Stocks27.79%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$14.43$14.43$14.43
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 242751-15
Oct, 242751-15
Sep, 242751-15
Aug, 242751-15
Jul, 24-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

Reported
Avg Forecast
High Forecast
Low Forecast
Surprise %

Revenue Forecast

Reported
Avg Forecast
High Forecast
Low Forecast
Surprise %

Net Income Forecast

Reported
Avg Forecast
High Forecast
Low Forecast
Surprise %

RGC Forecast FAQ

Is Regencell Bioscience stock a buy?

Regencell Bioscience stock has a consensus rating of Hold, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regencell Bioscience is a neutral investment for most analysts.

What is Regencell Bioscience's price target?

Regencell Bioscience's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $14.43.

How does Regencell Bioscience stock forecast compare to its benchmarks?

Regencell Bioscience's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (19.91%) and underperforming the specialty & generic drug manufacturers stocks industry (27.79%).

What is the breakdown of analyst ratings for Regencell Bioscience over the past three months?

  • November 2024: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 6.67% Sell, 0% Strong Sell.
  • October 2024: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 6.67% Sell, 0% Strong Sell.
  • September 2024: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 6.67% Sell, 0% Strong Sell.